Hypothesis

We hypothesize that aging endothelial cells release exosomes enriched in miR-21-5p that directly drive vascular smooth muscle cell (VSMC) phenotypic switching toward an osteogenic lineage, increasing medial calcification and arterial stiffness, even when nitric oxide (NO) bioavailability remains low.

Mechanistic Rationale

Endothelial dysfunction is the earliest hallmark of vascular aging, characterized by reduced NO synthase activity, increased oxidative stress, and senescence-associated secretory phenotype (SASP) release {1}. Senescent endothelial cells not only secrete cytokines but also package specific microRNAs into exosomes that influence neighboring cells. Recent work shows miR-21-5p is upregulated in senescent endothelial exosomes and can activate RUNX2 in VSMCs, promoting osteogenic differentiation and calcification {2}. Calcified VSMCs contribute to arterial stiffening by increasing medial calcium deposition and reducing elastin integrity, a process that proceeds independently of NO-mediated vasodilation {3}.

Thus, a senescence‑exosome‑miR-21‑5p axis could constitute a parallel route linking endothelial aging to stiffness, bypassing the classical NO‑dependent mechanosensing loop.

Testable Predictions

1. In aged mice, plasma levels of endothelial‑derived exosomes carrying miR-21-5p will positively correlate with carotid‑femoral pulse wave velocity (cfPWV).
2. Pharmacological inhibition of neutral sphingomyelinase‑2 (nSMase2) with GW4869 to block exosome release will reduce miR-21-5p exosomal load, decrease VSMC RUNX2 activity, lower medial calcification, and decrease cfPWV, without significantly restoring NO metabolites.
3. Conversely, systemic administration of synthetic miR-21‑5p‑loaded exosomes to young mice will increase VSMC osteogenic markers and elevate cfPWV despite normal NO levels.

Experimental Approach

• Animals: Young (3 mo) and aged (24 mo) C57BL/6 mice; groups receive vehicle, GW4869 (1 mg/kg i.p. thrice weekly), or control exosomes.
• Readouts: cfPWV via Doppler; plasma exosome miR-21-5p by qPCR after CD31‑immunocapture; NO metabolites (nitrate/nitrite) via Griess; VSMC calcification ex vivo (Alizarin Red staining of aortic sections); RUNX2 and osteocalcin expression by Western blot.
• Timeline: 4‑week treatment; measurements at baseline and endpoint.

Potential Outcomes and Falsifiability

If GW4869 lowers cfPWV without improving NO bioavailability, the hypothesis is supported. If cfPWV remains unchanged despite reduced exosomal miR-21-5p, or if NO restoration alone normalizes PWV, the hypothesis is falsified, indicating that endothelial‑derived exosomal miR-21-5p is not a causal driver of stiffness independent of NO.

This framework provides a clear, falsifiable path to test whether targeting endothelial exosomal signaling can break the endothelial‑stiffness reinforcement loop, offering a novel therapeutic avenue complementary to NO‑centric strategies.